Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Predicting Adult-Onset Autoimmune Diabetes

Clarity From Complexity

  1. R. David Leslie
  1. From the Blizard Institute of Cell and Molecular Science, London, U.K.
  1. Corresponding author: R. David Leslie, r.d.g.leslie{at}qmul.ac.uk.
Diabetes 2010 Feb; 59(2): 330-331. https://doi.org/10.2337/db09-1620
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

“What is time?” asked Saint Augustine in his Confessions, “When someone asks me, I know. But as soon as someone comes to question me on this matter, and I try to explain, I don't know anymore.” A physician asked to define an autoimmune disease has a similar sense of frustration. For the perplexed, three features of autoimmune diseases, derived from Witebsky's postulates, might help: 1) the presence of defined autoantigens and autoantibodies; 2) passive transfer of T-lymphocytes, which leads to disease development; and 3) successful immunomodulation of disease (1). Indeed, for type 1 diabetes in humans we know that autoantibodies are common and, alas, also that the second postulate is unethical and the third controversial. In reality, a disease is considered autoimmune when target organ destruction is allied to the presence of disease-specific target organ autoantibodies (2). It is through their clinical phenotype that diseases gain identity; only recently have we used genetic and immune responses to adapt disease names. Therefore, the historical characteristic of severe diabetes as childhood-onset disease was supplanted by insulin-dependent diabetes and with identification of diabetes-associated autoantibodies and genetic susceptibility through the major histocompatibilty complex (MHC) for type 1 diabetes, or more precisely type 1a diabetes, with type 2 diabetes being everything type 1 diabetes was not (2,3).

From the earliest years it was apparent that childhood diabetes was not always insulin dependent and vice versa. A revised classification of type 1 diabetes recognized as much when it excluded the term insulin dependent, thereby also excluding two features, ketoacidosis and insulin therapy, which were previously regarded as categorical features of this disease (3). Further complexity ensued with the recognition that a proportion of patients with ketosis-prone diabetes can stop insulin therapy, whereas 5–10% of adult-onset noninsulin-requiring diabetic patients have diabetes-associated autoantibodies (4,5). Indeed, adult-onset autoimmune diabetes is only one form of a broad spectrum of autoimmune diabetes, whether viewed genetically, immunologically, metabolically, or clinically (Fig. 1). When viewed genetically, MHC susceptibility, typical of autoimmune diabetes, is less striking in adulthood (6). From the immunological perspective, autoimmune diabetes is characterized by autoantibodies, although their number in a given subject declines with increasing age at onset (7). Metabolically, insulin secretory loss, but not insensitivity, is less pronounced in adulthood (8,9). From the clinical aspect, noninsulin-requiring autoimmune diabetes is most prevalent in adulthood (10). Adult autoimmune diabetic patients who are initially noninsulin requiring have latent autoimmune diabetes of adults (LADA), which is latent because without testing for diabetes-associated autoantibodies patients masquerade clinically as having type 2 diabetes (5). Other acronyms include slowly progressing insulin-dependent diabetes (SPIDM) or type 1.5 diabetes. Clinicians, in reality, still use their clinical nose to identify type 1a diabetes without routinely checking for autoantibodies, e.g., those for GAD (GADA). But, in maintaining a clinical rather than an immunogenetic definition, something is lost. It follows that the best way to identify autoimmune diabetes is to assess diabetes-associated autoantibodies, which represent the only relevant categorical trait (3,4,5,10).

FIG. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIG. 1.

The spectrum of autoimmune diabetes extends across all ages and varies with age at diagnosis. Older patients are more likely to have appreciable C-peptide but less likely to have high-risk MHC genes, have multiple autoantibodies, and require insulin treatment. T1DM, type 1 diabetes.

Although there is no evidence that autoantibodies cause autoimmune diabetes, they share guilt by association. It follows that: 1) autoantibodies predict autoimmune diabetes irrespective of the age at which they are detected and 2) the antigen could be used for immunomodulation therapy to alter the disease process. In this issue of Diabetes, Lundgren et al. report firm evidence of the former, allied to recent evidence of the latter (11). Lundgren et al. confirm and extend an earlier study by showing that GADA, in a large cohort (initially 4,976 subjects were screened) of adult nondiabetic relatives of type 2 diabetic patients, are significant predictors of diabetes (12). A subgroup of this cohort was followed for 8 years: 252 subjects with GADA and 2,511 subjects without GADA. If GADA truly predicted diabetes, then every nondiseased subject with the autoantibody would eventually develop the disease (high positive predictive value); however, that value, albeit highly significant, was only 14%. Because this cohort was enriched for GADA positivity, even that predictive figure is exaggerated. Nevertheless, several additional factors could have increased the predictive power. First, limited specificity of the GADA assay means that ≥50 patients had false-positive GADA. Given such a large cohort, the assay specificity in recent years fell to 91%. Repeat testing and testing for multiple antibodies would have limited false positivity. Indeed, the predictive power was increased in those who sero-converted, or had high titer GADA. Second, addition of genetic and metabolic biomarkers, the latter tested prospectively, would increase predictive power similar to that for children at risk (8,13). Of note, many individuals with diabetes-associated autoantibodies do not develop diabetes, especially when identified at an older age. In this case, they reflect islet cell antibodies detected in first-degree relatives of type 1 diabetic patients in whom older age is also associated with lower risk of progression to diabetes (14). Further, in line with the proposal that adult-onset autoimmune diabetes is usually noninsulin requiring, all but 3 of 36 patients who developed diabetes had a non–insulin-dependent phenotype 1 year postdiagnosis, i.e., they had LADA (11).

The purpose of prediction is prevention. Given that the predictive power of GADA for diabetes in children now extends to adults, albeit less impressively, can we prevent autoimmune diabetes? Certainly, we can modify the disease process in established diabetes, as illustrated by recent studies using alum-formulated GAD. Two injections of GAD, given 30 days apart to GADA-positive childhood-onset and adult-onset autoimmune diabetic patients, affected serum C-peptide levels after 2 and 5 years, respectively (15,16). It was no less remarkable that the effect was modest than that there was any effect. Alum-formulated GAD, among other approaches, is now to be given in the pre-diabetic period, when we anticipate it would have a substantially greater impact. There was a time when predicting autoimmune diabetes was beyond our imagination. However, the change in disease definition, in association with the identification of disease-associated autoantibodies, has brought diabetes prediction within our grasp. For the perplexed, clarity has come from complexity and, with it, the real potential of disease prevention.

ACKNOWLEDGMENTS

No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying original article, p. 416.

  • Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

  • © 2010 by the American Diabetes Association.

REFERENCES

  1. ↵
    1. Rose NR,
    2. Bona C
    : Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993;14:426–430
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Bach JF
    : The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911–920
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183–1197
    OpenUrlFREE Full Text
  4. ↵
    1. Balasubramanyam A,
    2. Garza G,
    3. Rodriguez L,
    4. Hampe CS,
    5. Gaur L,
    6. Lernmark A,
    7. Maldonado MR
    : Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006; 29: 2575– 2579
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Naik RG,
    2. Brooks-Worrell BM,
    3. Palmer JP
    : Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009;94:4635–4644
    OpenUrlCrossRefPubMed
  6. ↵
    1. Cervin C,
    2. Lyssenko V,
    3. Bakhtadze E,
    4. Lindholm E,
    5. Nilsson P,
    6. Tuomi T,
    7. Cilio CM,
    8. Groop L
    : Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008;57:1433–1437
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Sabbah E,
    2. Savola K,
    3. Ebeling T,
    4. Kulmala P,
    5. Vähäsalo P,
    6. Ilonen J,
    7. Salmela PI,
    8. Knip M
    : Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000;23:1326–1332
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Sosenko JM,
    2. Palmer JP,
    3. Greenbaum CJ,
    4. Mahon J,
    5. Cowie C,
    6. Krischer JP,
    7. Chase HP,
    8. White NH,
    9. Buckingham B,
    10. Herold KC,
    11. Cuthbertson D,
    12. Skyler JS
    : Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006;29:643–649
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hawa MI,
    2. Thivolet C,
    3. Mauricio D,
    4. Alemanno I,
    5. Cipponeri E,
    6. Collier D,
    7. Hunter S,
    8. Buzzetti R,
    9. de Leiva A,
    10. Pozzilli P,
    11. Leslie RD
    Action LADA Group. Metabolic syndrome and autoimmune diabetes: Action LADA 3. Diabetes Care 2009; 32:160–164
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Leslie RD,
    2. Delli Castelli M
    : Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004; 53: 3033– 3040
    OpenUrlFREE Full Text
  11. ↵
    1. Lundgren VM,
    2. Isomaa B,
    3. Lyssenko V,
    4. Laurila E,
    5. Korhonen P,
    6. Groop LC,
    7. Tuomi T
    the Botnia Study Group. GAD antibody positivity predicts type 2 diabetes in an adult population. Diabetes 2010; 59:416–422
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Hampe CS,
    2. Hall TR,
    3. Agren A,
    4. Rolandsson O
    : Longitudinal changes in epitope recognition of autoantibodies against glutamate decarboxylase 65 (GAD65Ab) in prediabetic adults developing diabetes. Clin Exp Immunol 2007; 148: 72– 78
    OpenUrlPubMed
  13. ↵
    1. Orban T,
    2. Sosenko JM,
    3. Cuthbertson D,
    4. Krischer JP,
    5. Skyler JS,
    6. Jackson R,
    7. Yu L,
    8. Palmer JP,
    9. Schatz D,
    10. Eisenbarth G
    ; Diabetes Prevention Trial-1Study Group. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 59:2269–2274
    OpenUrl
  14. ↵
    1. Sosenko JM,
    2. Krischer JP,
    3. Palmer JP,
    4. Mahon J,
    5. Cowie C,
    6. Greenbaum CJ,
    7. Cuthbertson D,
    8. Lachin JM,
    9. Skyler JS
    ; Diabetes Prevention Trial-Type 1 Study Group. A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. Diabetes Care 2008; 31: 528– 533
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Ludvigsson J,
    2. Faresjö M,
    3. Hjorth M,
    4. Axelsson S,
    5. Chéramy M,
    6. Pihl M,
    7. Vaarala O,
    8. Forsander G,
    9. Ivarsson S,
    10. Johansson C,
    11. Lindh A,
    12. Nilsson NO,
    13. Aman J,
    14. Ortqvist E,
    15. Zerhouni P,
    16. Casas R
    : GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909–1920
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Agardh CD,
    2. Lynch KF,
    3. Palmér M,
    4. Link K,
    5. Lernmark A
    : GAD65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009;52:1363–1368
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top

In this Issue

February 2010, 59(2)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predicting Adult-Onset Autoimmune Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Predicting Adult-Onset Autoimmune Diabetes
R. David Leslie
Diabetes Feb 2010, 59 (2) 330-331; DOI: 10.2337/db09-1620

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Predicting Adult-Onset Autoimmune Diabetes
R. David Leslie
Diabetes Feb 2010, 59 (2) 330-331; DOI: 10.2337/db09-1620
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • ACKNOWLEDGMENTS
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.